<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598451</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1904</org_study_id>
    <nct_id>NCT04598451</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)</brief_title>
  <acronym>ADDRESS</acronym>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized, double-blinded, placebo-controlled trial to&#xD;
      investigate the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK,&#xD;
      and PD of efgartigimod PH20 SC in adult participants aged from 18 years with PV or PF. The&#xD;
      trial comprises a screening period of up to 3 weeks, a treatment period of up to 30 weeks,&#xD;
      and an 8-week follow-up period for participants who do not enroll into the open-label&#xD;
      extension (OLE) trial ARGX-113-1905. The primary objective of the ARGX-113-1904 trial is to&#xD;
      demonstrate the efficacy of subcutaneous administration of efgartigimod co-formulated with&#xD;
      recombinant human hyaluronidase PH20 (Efgartigimod PH20 SC) compared to placebo in the&#xD;
      treatment of participants with Pemphigus Vulgaris (PV). Secondary objectives are to also&#xD;
      demonstrate the efficacy of efgartigimod PH20 SC in the treatment of participants with&#xD;
      Pemphigus Foliaceus (PF), and to demonstrate early onset of action and a prednisone-sparing&#xD;
      effect. After confirmation of eligibility, participants will be randomized in a 2: 1 ratio to&#xD;
      receive efgartigimod PH20 SC or placebo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Pemphigus Vulgaris (PV) participants who achieve complete clinical remission (CR) on minimal Prednisone therapy</measure>
    <time_frame>30 weeks treatment period</time_frame>
    <description>Proportion of Pemphigus Vulgaris participants who achieve Clinical Remission on minimal Prednisone therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) participants who achieve complete clinical remission (CR) on minimal Prednisone therapy</measure>
    <time_frame>30 weeks treatment period</time_frame>
    <description>Proportion of Pemphigus Vulgaris and Pemphigus Foliaceus participants who achieve complete clinical remission on minimal Prednisone therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative prednisone dose over the trial in Pemphigus Vulgaris participants</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Cumulative prednisone dose over the trial in Pemphigus Vulgaris participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete clinical remission in Pemphigus Vulgaris participants</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Time to complete clinical remission in Pemphigus Vulgaris participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Control (DC) in Pemphigus Vulgaris (PV) participants</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Time to Disease Control in Pemphigus Vulgaris participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Pemphigus Foliaceus (PF) participants who achieve complete clinical remission (CR) on minimal prednisone therapy</measure>
    <time_frame>30 weeks treatment period</time_frame>
    <description>Proportion of Pemphigus Foliaceus (PF) participants who achieve complete clinical remission (CR) on minimal prednisone therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative prednisone dose over the trial in Pemphigus Vulgaris and Pemphigus Foliaceus participants</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Cumulative prednisone dose over the trial in Pemphigus Vulgaris and Pemphigus Foliaceus participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete clinical remission in Pemphigus Vulgaris and Pemphigus Foliaceus participants</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Time to complete clinical remission in Pemphigus Vulgaris and Pemphigus Foliaceus participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease control in Pemphigus Vulgaris and Pemphigus Foliaceus participants</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Time to disease control in Pemphigus Vulgaris and Pemphigus Foliaceus participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment failure</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Rate of treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of flare</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Rate of flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pemphigus Disease Area Index at each visit</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Pemphigus Disease Area Index at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events, Adverse Events of Special Interest, and Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Severity of Treatment-Emergent Adverse Events, Adverse Events of Special Interest, and Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) score</measure>
    <time_frame>30 weeks treatment period</time_frame>
    <description>EuroQol Five-Dimension Five-Level Scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoimmune Blister Quality of Life (ABQOL) score</measure>
    <time_frame>30 weeks treatment period</time_frame>
    <description>Autoimmune Blister Quality of Life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efgartigimod serum concentrations</measure>
    <time_frame>Up to 38 weeks</time_frame>
    <description>Efgartigimod serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total immunoglobulin G and subtype (IgG1, IgG2, IgG3, IgG4) serum levels</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Total immunoglobulin G and subtype (IgG1, IgG2, IgG3, IgG4) serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti desmoglein-1 and -3 autoantibodies serum levels</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Anti desmoglein-1 and -3 autoantibodies serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA) to efgartigimod PH20 SC (serum plasma)</measure>
    <time_frame>Up to 38 weeks</time_frame>
    <description>Anti-drug antibodies to efgartigimod PH20 SC (serum plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies produced against recombinant human hyaluronidase (rHuPH20) (plasma levels)</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Antibodies produced against recombinant human hyaluronidase (rHuPH20) (plasma levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Glucocorticoid Toxicity Index (C-GTI) comprising the Aggregate Improvement Score (AIS) and the Cumulative Worsening Score (CWS)</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Composite Glucocorticoid Toxicity Index comprising the Aggregate Improvement Score and the Cumulative Worsening Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants or caregivers completing the self-administration training</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Number of participants or caregivers completing the self-administration training</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants or caregivers completing the self-administration training</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Percentage of participants or caregivers completing the self-administration training</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants or caregivers determined by the site staff to be sufficiently competent to self-administer efgartigimod PH20 SC</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Number of participants or caregivers determined by the site staff to be sufficiently competent to self-administer efgartigimod PH20 SC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants or caregivers determined by the site staff to be sufficiently competent to self-administer efgartigimod PH20 SC</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Percentage of participants or caregivers determined by the site staff to be sufficiently competent to self-administer efgartigimod PH20 SC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants or caregivers that self-administer efgartigimod PH20 SC under site staff supervision</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Number of participants or caregivers that self-administer efgartigimod PH20 SC under site staff supervision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants or caregivers that self-administer efgartigimod PH20 SC under site staff supervision</measure>
    <time_frame>Up to 41 weeks</time_frame>
    <description>Percentage of participants or caregivers that self-administer efgartigimod PH20 SC under site staff supervision</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pemphigus Vulgaris</condition>
  <condition>Pemphigus Foliaceus</condition>
  <arm_group>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving efgartigimod PH20 SC on top of prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving placebo on top of prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod PH20 SC</intervention_name>
    <description>Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer</description>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Oral prednisone tablets</description>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the requirements of the trial, to provide written informed&#xD;
             consent (including consent for the use and disclosure of research-related health&#xD;
             information), willingness and ability to comply with the trial protocol procedures&#xD;
             (including required trial visits).&#xD;
&#xD;
          2. The participant is male or female, and aged from 18 years at the time of signing the&#xD;
             ICF.&#xD;
&#xD;
          3. The participant has a clinical diagnosis of PV (mucosal, cutaneous, mucocutaneous) or&#xD;
             PF which has been confirmed by cutaneous histology, positive direct immunofluorescence&#xD;
             (IF), and positive indirect IF and/or enzyme-linked immunosorbent assay (ELISA).&#xD;
&#xD;
          4. The participant meets one of the following profiles:&#xD;
&#xD;
               1. Newly diagnosed disease with PDAI ≥15 at baseline and naïve to treatment&#xD;
&#xD;
               2. Newly diagnosed disease with PDAI ≥15 while receiving a first course of oral&#xD;
                  prednisone (or equivalent). According to clinical judgment, the participant has&#xD;
                  shown no significant improvement of PV or PF signs for at least 2 weeks before&#xD;
                  baseline and is considered fit to start prednisone treatment at 0.5 mg/kg qd at&#xD;
                  baseline.&#xD;
&#xD;
               3. Experiencing flare with PDAI ≥15, a maximum of 4 years since diagnosis, and off&#xD;
                  prednisone therapy ± a conventional immunosuppressant (e.g., azathioprine,&#xD;
                  cyclophosphamide, methotrexate, mycophenolate mofetil) or dapsone. Note:&#xD;
                  conventional immunosuppressants and dapsone must be discontinued before baseline.&#xD;
&#xD;
               4. Experiencing flare with PDAI ≥15, a maximum of 4 years since diagnosis, and&#xD;
                  receiving a tapered dose of oral prednisone (or the equivalent), provided that&#xD;
                  prednisone has been given at stable dose ± a conventional immunosuppressant for&#xD;
                  at least 2 weeks and patients are fit to start prednisone treatment at 0.5 mg/kg&#xD;
                  qd at baseline.&#xD;
&#xD;
          5. Contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating clinical trials and:&#xD;
&#xD;
               1. Male participants: Male participants must agree to use acceptable method of&#xD;
                  contraception, and not donate sperm from signing the ICF until the end of the&#xD;
                  study.&#xD;
&#xD;
               2. Female participants: Women of childbearing potential must:&#xD;
&#xD;
                    -  have a negative serum pregnancy test at screening and negative urine&#xD;
                       pregnancy test at baseline before the IMP can be administered.&#xD;
&#xD;
                    -  agree to use a highly effective or acceptable contraception methods, which&#xD;
                       should be maintained at minimum until 90 days after the last dose of IMP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has a confirmed diagnosis of paraneoplastic pemphigus, drug-induced&#xD;
             pemphigus, pemphigus vegetans, pemphigus erythematosus, or any other non-PV/non-PF&#xD;
             autoimmune blistering disease.&#xD;
&#xD;
          2. Participants with mild disease severity as defined by PDAI &lt;15 at baseline.&#xD;
&#xD;
          3. Participants who show a significant improvement of PV or PF in the period from&#xD;
             screening to baseline according to clinical judgment (eg, the patient has achieved DC&#xD;
             or a substantial reduction in PDAI activity score during screening period).&#xD;
&#xD;
          4. The participant has been administered therapy(ies) other than oral prednisone or&#xD;
             conventional immunosuppressants (e.g., azathioprine, cyclophosphamide, methotrexate,&#xD;
             mycophenolate mofetil) or dapsone within 2 months before the baseline visit and that&#xD;
             can affect clinical disease activity. For example, excluded medications are&#xD;
             intravenous methylprednisolone, dapsone, sulfasalazine, tetracyclines, nicotinamide at&#xD;
             doses above the recommended daily allowance (RDA)/dietary reference intake (DRI),&#xD;
             plasmapheresis/ plasma exchange, immunoadsorption, and IVIg.&#xD;
&#xD;
          5. Use of any monoclonal antibody (including rituximab or another anti-CD20 biologic)&#xD;
             within 6 months before the baseline visit.&#xD;
&#xD;
          6. Known hypersensitivity to any of the components of the administered treatments.&#xD;
&#xD;
          7. The participant has a known contraindication to oral prednisone.&#xD;
&#xD;
          8. The participant has a history of refractory disease, as defined by a failure to&#xD;
             respond to first-line and second-line therapies&#xD;
&#xD;
          9. Participants who have a history of malignancy unless deemed cured by adequate&#xD;
             treatment with no evidence of recurrence for ≥3 years before first IMP administration.&#xD;
             Participants with any of the following cancers can be included at any time, provided&#xD;
             they are adequately treated prior to their participation in the study:&#xD;
&#xD;
               -  Basal cell or squamous cell skin cancer,&#xD;
&#xD;
               -  Carcinoma in situ of the cervix,&#xD;
&#xD;
               -  Carcinoma in situ of the breast,&#xD;
&#xD;
               -  Incidental histological finding of prostate cancer&#xD;
&#xD;
         10. Participants with clinical evidence of other significant serious disease or&#xD;
             participants who recently underwent or have planned a major surgery during the period&#xD;
             of the trial, or any other condition in the opinion of the investigator, that could&#xD;
             confound the results of the trial or put the patient at undue risk.&#xD;
&#xD;
         11. Pregnant and lactating women and those intending to become pregnant during the trial&#xD;
             or within 90 days after the last administration of IMP.&#xD;
&#xD;
         12. Current or history (i.e. within 12 months of screening) of alcohol, drug, or&#xD;
             medication abuse.&#xD;
&#xD;
         13. Any other known autoimmune disease that, in the opinion of the investigator, would&#xD;
             interfere with an accurate assessment of clinical symptoms of PV or PF or put the&#xD;
             participant at undue risk.&#xD;
&#xD;
         14. The participant has a Karnofsky Performance score &lt;60%.&#xD;
&#xD;
         15. Vaccination with live viral vaccines within 28 days prior to randomization.&#xD;
&#xD;
         16. The participant has clinically significant uncontrolled active or chronic bacterial,&#xD;
             viral, or fungal infection.&#xD;
&#xD;
         17. Positive serum test at screening for an active viral infection with any of the&#xD;
             following conditions: Hepatitis B Virus, Hepatitis C Virus , HIV.&#xD;
&#xD;
         18. The participant has total immunoglobulin G (IgG) &lt;6 g/L at screening.&#xD;
&#xD;
         19. The participant has previously participated in a trial with efgartigimod and has&#xD;
             received at least one administration of IMP.&#xD;
&#xD;
         20. Use of an investigational drug within 3 months or 5 half-lives of the drug (whichever&#xD;
             is longer) prior to first IMP administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Guglietta, MD</last_name>
    <phone>857-350-4834</phone>
    <phone_ext>+1</phone_ext>
    <email>ClinicalTrials@argenx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator site 77 - US0010086</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 97 - US0010091</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 44 - US0010101</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigator site 2 - US0010087</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 9 - US0010099</name>
      <address>
        <city>Florida City</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Investigator site 99 - US0010117</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 78 - US0010109</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 61 - US0010090</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 102 - US0010098</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 19 - US0010088</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203-1070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 60 - US0010096</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 20 - US0010094</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-1716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 73 - US00100</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 101 - US0010097</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 98 - US0010107</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 1 - US0010084</name>
      <address>
        <city>Dripping Springs</city>
        <state>Texas</state>
        <zip>78620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrial@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 88 - US0010114</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 59 - US0010106</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 24 - AU0610006</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 5 - AU0610007</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 30 - BG350012</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 31 - BG3590013</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 4 - BG3590010</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 3 - BG3590009</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 13 - BG3590011</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 34 - FR0330028</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 33 - FR0330027</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 46 - FR0330029</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 32 - FR0330026</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 63 - GE9950014</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 35 - GE9950013</name>
      <address>
        <city>Tbilisi</city>
        <zip>0162</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 36 - GE9950015</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 64 - DE0490029</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 48 - DE0490030</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 49 - DE0490024</name>
      <address>
        <city>Frankfurt am main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 47 - DE0490023</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 38 - DE0490028</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 37 - DE0490002</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 68 - DE0490001</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 25 - DE0490025</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 79 - DE0490027</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 21 - DE0490026</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 40 - GR0300004</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 51 - GR0300006</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 69 - GR0300001</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 39 - GR0300003</name>
      <address>
        <city>Chaïdári</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 50 - GR0300002</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 41 - GR0300005</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 22 - HU0360003</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 14 - HU0360001</name>
      <address>
        <city>Pécs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 42 - HU0360002</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 80 - IN0910002</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 100 - IN0910001</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 90 - IN0910004</name>
      <address>
        <city>Lucknow</city>
        <zip>226005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 91 - IN0910003</name>
      <address>
        <city>Nagpur</city>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 12 - ISR9720002</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 11 - IT0390006</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 52 - IT0390031</name>
      <address>
        <city>Firenze</city>
        <zip>50125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 92 - IT0390030</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 70 - IT0390038</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 43 - IT390005</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 71 - IT0390040</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 94 - JP0810046</name>
      <address>
        <city>Aichi</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 81 - JP0810040</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 85 - JP0810050</name>
      <address>
        <city>Kurume</city>
        <zip>830-001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 82 - JP0810042</name>
      <address>
        <city>Kōfu</city>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 84 - JP0810047</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 93 - JP0810041</name>
      <address>
        <city>Okayama</city>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 86 - JP0810049</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 74 - JP0810045</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 83 - JP0810043</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 26 - PL0480027</name>
      <address>
        <city>Katowice</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 95 - PL0480036</name>
      <address>
        <city>Poznań</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 27 - PL0480025</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 28 - PL0480028</name>
      <address>
        <city>Wrocław</city>
        <zip>50-566</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 72 - PL0480032</name>
      <address>
        <city>Łódź</city>
        <zip>90-647</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 54 - RU0070035</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 58 - RU0070033</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 57 - RU0070029</name>
      <address>
        <city>Kazan</city>
        <zip>420111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 55 - RU0070030</name>
      <address>
        <city>Krasnodar</city>
        <zip>350020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 53 - RU0070032</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 56 - RU0070031</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 65 - RU0070034</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 66 - RU0070028</name>
      <address>
        <city>Saratov</city>
        <zip>410012/410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 29 - ES0340026</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 15 - ES0340032</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio- Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 67 - ES0340034</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 10 - ES0340025</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invetistigator site 8 - ES0340029</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 6 - ES0340027</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 23 - ES0340031</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 7 - ES0340028</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 76 - TR0900020</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 75 - TR0900012</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 87 - TR0900011</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 89 - UA3800017</name>
      <address>
        <city>Dnipro</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 45 - UA3800023</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 16 - UA3800020</name>
      <address>
        <city>Kyiv</city>
        <zip>4050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 18 - UA3800019</name>
      <address>
        <city>Kyiv</city>
        <zip>4209</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 62 - UA3800021</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 17 - UA3800018</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 96 - UK0440022</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

